IQVIA Holdings Inc.
Financials
Valuation Metrics
IQVIA Holdings Inc.'s Market Cap is $38.95B. At end of 2025 it was $38.32B. Ranked #390 of 3,112 in US market (top 13%), #279 of 1,667 on NYSE (top 17%), #21 of 206 in Health Care Equipment & Services (top 10%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $38.95B | US#390/3,112 Sec#21/206 |
| Revenue | $16.98B | US#375/3,112 Sec#26/206 |
| Net Income | $1.38B | US#421/3,112 Sec#22/206 |
| Total Assets | $29.88B | US#479/3,112 Sec#24/206 |
| Net Assets | $6.17B | US#609/3,112 Sec#37/206 |
| Employees | 93,000 | US#86/3,112 Sec#8/206 |
| Value | ||
| P/E | 28.33x | US#1,409/3,112 Sec#47/206 |
| P/B | 6.31x | US#2,346/3,112 Sec#155/206 |
| P/S | 2.29x | US#1,407/3,112 Sec#104/206 |
| EV/EBITDA | 15.10x | US#1,498/3,112 Sec#60/206 |
| FCF Yield | 7.69% | US#777/3,112 Sec#30/206 |
| Profitability | ||
| ROE | 22.28% | US#484/3,112 Sec#24/206 |
| ROA | 4.60% | US#1,075/3,112 Sec#66/206 |
| Op. Margin | 13.57% | US#1,326/3,112 Sec#55/206 |
| Revenue Growth | 8.74% | US#1,394/3,112 Sec#99/206 |
| Earnings Growth | -3.76% | US#1,465/3,112 Sec#74/206 |
| Financial Health | ||
| Debt Ratio | 382.11% | US#2,259/3,112 Sec#181/206 |
| Total Debt | $16.24B | US#275/3,112 Sec#11/206 |
| FCF | $2.99B | US#250/3,112 Sec#18/206 |
| Cash | $1.91B | US#437/3,112 Sec#25/206 |
| Current Ratio | 0.71x | US#2,579/3,112 Sec#205/206 |
| Net Debt/EBITDA | 4.06x | US#1,887/3,112 Sec#119/206 |
| Performance | ||
| 1Y Return | 27.92% | US#1,270/3,112 Sec#83/206 |
| 1M Return | 12.73% | US#385/3,112 Sec#35/206 |
| From 52W High | -7.15% | US#763/3,112 Sec#53/206 |
| 1Y MDD | -35.87% | US#1,739/3,112 Sec#86/206 |
| Trading | ||
| Volume | 1,320,908 shares | US#1,235/3,112 Sec#79/206 |
| Trading Value | $309M | US#342/3,112 Sec#27/206 |
| Per Share | ||
| EPS | $8.00 | US#347/3,112 Sec#27/206 |
| BPS | $38.25 | US#626/3,112 Sec#42/206 |
Company Info
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. is based in Durham, North Carolina.